Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: Safety and two-year efficacy results from a multicentre, single-arm, phase II study

British Journal of Cancer

Volumn 111, Issue 8, 2014, Pages 1519-1525

  Sehouli, J ^a,b   Reinthaller, A ^c   Marth, C ^d   Reimer, D ^b   Reimer, T ^e   Stummvoll, W ^f   Angleitner Boubenizek, L ^f   Brandt, B ^g   Chekerov, R ^b  

^a NOGGO Ovarian Cancer Study Group of the North Eastern German Society of Gynaecological Oncology (NOGGO)   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f Salzburger Landeskliniken   (Austria)

^g Fresenius Biotech   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CATUMAXOMAB;

ADULT; AGED; CLINICAL TRIAL; FEMALE; HUMAN; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PEROPERATIVE CARE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE;

ADULT; AGED; ANTIBODIES, BISPECIFIC; FEMALE; HUMANS; INTRAOPERATIVE CARE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSTOPERATIVE CARE;

EID: 84908869591     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.443     Document Type: Article

References (25)

1. Aebi S, Castiglione M. On behalf of the ESMO Guidelines Working Group (2009) Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4): 21-23.
2. Bast Jr RC (2011) Molecular approaches to personalizing management of ovarian cancer. Ann Oncol 22(Suppl 8): viii5-viii15.
3. Burges A,Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13: 3899-3905.
4. Chan DL, Morris DL, Rao A, Chua TC (2012) Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res 4: 413-422.
5. Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130: 493-498.
6. Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J (2013) Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. Int J Gynecol Cancer 23: 268-275.
7. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGOOVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115: 1234-1244.
8. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403.
9. Grabowski JP, Harter P, Hils R, Lorenz D, Kaub C, Barinoff J, Heitz F, Traut A, du Bois A (2012) Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer. Gynecol Oncol 126: 54-57.
10. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien PM (2004) Overexpression of the cell adhesion molecules DDR1, claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 10: 4427-4436.
11. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127: 2209-2221.
12. Kaye SB (2007) Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol 25: 5150-5152.
13. Lutz AM, Willmann JK, Drescher CW, Ray P, Cochran FV, Urban N, Gambhir SS (2011) Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology 259: 329-345.
14. Monk BJ, Dalton H, Farley JH, Chase DM, Benjamin I (2013) Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol 86: 161-175.
15. Ozols RF (2006) Challenges for chemotherapy in ovarian cancer. Ann Oncol 17(Suppl 5): v181-v187.
16. Rafii A, Stoeckle E, Jean-Laurent M, Ferron G, Morice P, Houvenaeghel G, Lecuru F, Leblanc E, Querleu D (2012) Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer. PLoS One 7(7): e39415.
17. Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H (2007) Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 97: 315-321.
18. Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98: 2526-2534.
19. Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, Gülten OO (2009) Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol 99: 424-427.
20. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG (2006) Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 103: 483-488.
21. Teo M (2010) Peritoneal-based malignancies and their treatment. Ann Acad Med Singapore 39: 54-57.
22. Tsujioka H, Yotsumoto F, Hikita S, Ueda T, Kuroki M, Miyamoto S (2011) Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Curr Opin Obstet Gynecol 23: 24-30.
23. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35: 122-128.
24. Woopen H, Sehouli J (2009) Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res 29: 3353-3359.
25. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, LindhoferH (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163: 1246-1252.